Lipid-based nanomedicines for the treatment of bacterial respiratory infections: current state and new perspectives
The global threat posed by antimicrobial resistance demands urgent action and the development of effective drugs. Lower respiratory tract infections remain the deadliest communicable disease worldwide, often challenging to treat due to the presence of bacteria that form recalcitrant biofilms. There is consensus that novel anti-infectives with reduced resistance compared with conventional antibiotics are needed, leading to extensive research on innovative antibacterial agents. This review explores the recent progress in lipid-based nanomedicines developed to counteract bacterial respiratory infections, especially those involving biofilm growth; focuses on improved drug bioavailability and targeting and highlights novel strategies to enhance treatment efficacy while emphasizing the importance of continued research in this dynamic field.
| Main Authors: | , , , , |
|---|---|
| Other Authors: | |
| Format: | artículo de revisión biblioteca |
| Published: |
Taylor & Francis
2024
|
| Subjects: | antimicrobial resistance, bacterial respiratory infections, biofilm, drug delivery, lipid nanoparticles, nanomedicine, targeting, |
| Online Access: | http://hdl.handle.net/10261/358160 http://dx.doi.org/10.13039/501100004837 http://dx.doi.org/10.13039/100012818 http://dx.doi.org/10.13039/501100004587 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|